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Summary
Streptogramin antibiotics are comprised of two dis-
tinct chemical components: the type A polyketides and
the type B cyclic depsipeptides. Clinical resistance to
the type B streptogramins can occur via enzymatic
degradation catalyzed by the lyase Vgb or by target
modification through the action of Erm ribosomal RNA
methyltransferases. We have prepared through chem-
ical and chemo-enzymatic approaches a series of
chimeric antibiotics composed of elements of type B
streptogramins and the membrane-active antibiotic
tyrocidine that evade these resistance mechanisms.
These new compounds show broad antibiotic activity
against gram-positive bacteria including a number of
important pathogens, and chimeras appear to func-
tion by a mechanism that is distinct from their parent
antibiotics. These results allow for the development
of a brand new class of antibiotics with the ability to
evade type B streptogramin-resistance mechanisms.
Introduction
Despite being discovered over 50 years ago, the strep-
togramin antibiotics have only recently seen significant
clinical use [1]. The semisynthetic streptogramin formu-
lation Synercid was approved by the FDA in 1999 for
the treatment of serious life-threatening infections
caused by antibiotic resistant gram-positive bacterial
pathogens such as vancomycin-resistant enterococci
[2, 3]. Streptogramins are produced by various soil bac-
teria of the genus Streptomyces and consist of two
chemically distinct components: type A and type B. The
type A streptogramins are cyclic hybrid peptide-poly-
ketide macrolactones [4]. Type B streptogramins are
cyclic depsipeptides consisting of 6–7 amino acids.
These peptides are cyclized via an ester bond between
the C-terminal carboxyl group and the secondary hy-
droxyl group of an invariant Thr residue at position 2.
The mode of action of both type A and type B strepto-
gramins is through inhibition of translation by binding
to bacterial ribosomes [5]. The available evidence indi-
cates that binding of the type A component facilitates
binding of the type B streptogramins, a phenomenon
that results in synergy of action and bacterial cell death
[6]. Recent X-ray structure analysis of the 50S ribo-
somal subunit in complex with these antibiotics has re-*Correspondence: wrightge@mcmaster.cavealed that type B streptogramins block the peptide
exit tunnel while the type A streptogramins bind to the
peptidyl transfer center [7].
The only clinically approved streptogramin in North
America, Synercid, is a combination of dalfopristin
(type A), and quinupristin (type B). Despite the relatively
recent clinical introduction of this antibiotic, resistance
to each component is well documented (reviewed in
[8]). This may be the result of the fact that streptogram-
ins have long been used in agriculture as animal growth
promotion agents. In fact, studies have shown that
commercial meat products can be contaminated with
streptogramin-resistant organisms [9–11].
Resistance to the type B streptogramins can result
from active efflux (Msr pumps), alteration of the target
ribosome by methylation of the 23S rRNA (Erm methyl-
transferases), and by the inactivating enzyme Vgb. Vgb
was originally found in streptogramin-resistant Staphy-
lococcus aureus [12] but has now been identified in
other gram-positive bacteria such as Enterococcus
faecium [13]. The enzyme was thought to be a hydro-
lase but has now been determined to be a lyase that
linearizes the cyclic depsipeptide through a novel elimi-
nation reaction [14]. This reaction results in cleavage of
the ester bond between the C terminus of the peptide
and a secondary hydroxyl group derived from the Thr
residue found at position 2 of the type B strepto-
gramin peptide.
This vulnerable and invariant ester bond arises as a
result of the action of a cyclizing thioesterase (TE) dur-
ing nonribosomal peptide biosynthesis of the antibiotic
[15]. We reasoned that isosteric replacement of this
ester bond with a more stable amide could result in
streptogramin analogs that were not susceptible to the
action of Vgb. We report here the preparation and bio-
logical evaluation of chimeric streptogramin-tyrocidine
peptides that are cyclized via amide rather than ester
bonds and are impervious to inactivation by Vgb or
methylation of the ribosome by Erm.
Results and Discussion
Design and Antibacterial Activity of Streptogramin-
Tyrocidine Chimeras
We reasoned that replacement of the ester linkage be-
tween the C-terminal carboxyl and side chain alcohol
derived from Thr at position 2 with the more thermody-
namically stable amide functionality could result in type
B streptogramins that were not substrates for the Vgb
lyase. We approached the synthesis of such peptides
using two solid phase strategies: a biomimetic ap-
proach using on-bead enzyme catalyzed cyclization
and a chemical method using base-assisted cyclization
(Figure 1).
Macrocyclic antibiotics are biosynthesized by poly-
ketide synthetases and nonribosomal peptide synthe-
tases. Prior to cyclization, these antibiotics are tethered
to carrier proteins and a cognate thioesterase catalyses
their release and cyclization if appropriate. Kohli et al.
Chemistry & Biology
230F
cFigure 1. Solid-Phase Chemoenzymatic and Chemical Strategies
Employed in Chimeric Peptide Synthesiswhave shown that this in vivo process can be mimicked
Tfor tyrocidine using solid phase peptide synthesis on
WPEGA resin and recombinant tyrocidine thioesterase
s(TycC TE), providing an efficient route for the synthesis
tof cyclic peptide antibiotics [16, 17]. The TycC TE pos-
msesses the ability to cyclize a variety of tyrocidine ana-
tlogs varying in length and functional groups [18, 19].
uHowever, there are certain steric restrictions with re-
Ospect to the amino acids incorporated into the peptide
ethat allow the TE to function efficiently [20]. For exam-
iple, it was determined that critical residues required
tfor efficient cyclization via TycC TE were D-Phe1 and
wL-Orn9. Changing L-Leu10 did not abolish cyclization;
chowever a 4-fold decrease in kcat was detected. De-
tspite these restrictions, we felt that this approach could
tfacilitate the synthesis of cyclic tyrocidine analogs with
vproperties and constituents of type B streptogramin
peptides (Figure 2).
iWe designed the chimeric peptides based on the di-
pversity of type B streptogramin chemical structures
w(summarized in Table 1), knowledge of the important
ocontact points of streptogramin B with the ribosome
f[7], and the steric constraints for TycC TE established
tin [20]. Since type B streptogramins occur both as cy-
aclic hexa- and heptadepsipeptides (not counting the
1extracyclic 3-Hpa group), we synthesized both lengths
1in our chimeras. The hexadepsipeptides 1–4, the hepta-
lpeptides 5 and 6, and the hexapeptide 7 (Figure 3, Ta-
sble 1) were initially prepared on PEGA resin and cy-
wclized using the recombinant TycC TE.
Incubation of TycC TE with the resin-bound linear
precursors resulted in cyclization of these peptides as A
Odetermined by LC-MS. This indicated that TycC TE was
not only capable of cyclizing tyrocidine analogs, but m
twas also capable of cyclizing our designed tyrocidine-
streptogramin chimeras. These results are consistent tigure 2. Dissection of Streptogramin-Tyrocidine Chimeric Antimi-
robial Peptidesith previous observations that the active site of TycC
E can accommodate a wide variety of substrates [20].
hile this enzymatic approach was successful as as-
essed by LC-MS analysis, the peptides were only ob-
ained in extremely low yields (<1 mg). Partially purified
aterial from these reactions was used to test their an-
ibiotic properties in disk diffusion susceptibility assays
sing E. coli BAS901. This strain is deficient in the Imp/
stA outer membrane protein, which is involved in cell
nvelope biogenesis [21, 22] and as a result exhibits
ncreased outer membrane permeability and suscep-
ibility to antibiotics, and increased susceptibility to-
ard organic solvents [23, 24]. This assay showed that
ompounds 5, 6, and 7 blocked cell growth, and impor-
antly that these compounds retained antibacterial ac-
ivity even in the presence of the streptogramin inacti-
ating enzyme Vgb (Table 2).
In an effort to improve the yield of chimeric antibiot-
cs, an alternative nonenzymatic method recently re-
orted by Qin et al. [25] for the cyclization of tyrocidine
as explored. This approach uses 20% DIPEA in THF
n a solid phase support adopting a “safety-catch” sul-
onamide linker [26] with activation by cyanomethyla-
ion to facilitate peptide cyclization [27]. Modifying this
pproach, 10 mg of purified cyclic compound 5 (Figure
, path B) was obtained and its structure confirmed via
H, 13C-NMR and mass spectrometry. For this study, we
imited our efforts to study of compound 5 as initial re-
ults as reported in Table 2 indicated that 5, 6, and 7
ere comparably active.
ntibacterial Properties of Compound 5
n-resin chemical cyclization of 5 provided sufficient
aterial for more extensive analysis of antibacterial ac-
ivity and investigation of its ability to inhibit the strep-
ogramin inactivating enzyme Vgb. This enzyme how-
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231Table 1. Amino Acid Sequences of Antimicrobial Peptides
Antibiotic AA1a AA2 AA3 AA4 AA5 AA6 AA7 AA8 AA9 AA10
Pristinamycin IA 3-Hpa Thr dAbu Pro N-Me-DMAPhe 4-Oxo Pip Phg
Virginiamycin S1 3-Hpa Thr dAbu Pro N-MePhe 4-Oxo Pip Phg
Patricin A 3-Hpa Thr dAbu Pro N-MePhe Pro Phg
Etamycin 3-Hpa Thr dLeu dHyp Sar DMLeu Ala PheSar
Compound 1 Bz-3-Hpa Thr dAbu Leu dPhe Pro Phg
Compound 2 Bz-3-Hpa Thr Orn Leu dPhe Pro Phg
Compound 3 Pic Thr dAbu Leu dPhe Pro Phg
Compound 4 Pic Thr Orn Leu dPhe Pro Phg
Compound 5 3-Hpa Dap Thr Orn Leu dPhe Pro Phe
Compound 6 3-Hpa Dap dAbu Orn Leu dPhe Pro Phg
Compound 7 3-Hpa Dap Orn Leu dPhe Pro Phg
Compound 8 3-Hpa Dap dAbu Pro Phe Pro Phg
Tyrocidineb Gln Tyr Val Orn Leu dPhe Pro Phe dPhe Asn
aAbbreviations: Abu, α-aminobutyric acid; Dap, diaminopropionic acid; DMLeu, N,β-dimethylleucine; 3-Hpa, 3-hydroxypicolonic acid; Hyp,
hydroxyproline; N-MePhe, N-methylphenylalanine; N-Me-DMAPhe, N-methyl-p-dimethylaminophenylalanine; 4-Oxo Pip, 4-Oxopipecolic acid;
Phg, phenylglycine; Pic, picolinic acid; Pip, pipecolic acid; Sar, sarcosine; PheSar, phenylsarcosine.
bTyrocidine is a 10 amino acid macrocycle shown for comparison to the synthesized peptides.The mechanism for the weak activity against Staphylo-bacteria (Table 2). Compound 5 demonstrated growth
Figure 3. Structures of Antimicrobial Pep-
tides Synthesized and Assayed in This Workever was insensitive to 5 in concentrations of up to 0.4
mM. We had previously synthesized an isosteric amide
analog of the minimal Vgb substrate Hpa-Thr(OPhg)-
OMe [14]. This analog also was not an inhibitor of Vgb
at concentration of up to 1 mM (unpublished). These
observations suggest that the ester bond may be cru-
cial for substrate binding within the active site of the
enzyme, although this possibility awaits analysis of the
3D structure of the inactivating enzyme. Regardless of
the actual mechanism, our design of these strepto-
gramin-tyrocidine chimeras resulted in antibiotics that
are not recognized by a streptogramin inactivation
enzyme.
In vivo antibacterial activity of 5 was further explored
using a variety of gram-positive and gram-negativeinhibition activity against the hyperpermeable gram-
negative bacterium E. coli BAS901, but not wild-type
E. coli 25922 or other gram-negative bacteria including
Salmonella enterica serovar Typhimurium and Haemo-
philus influenzae. On the other hand, 5 was active
against the gram-positive bacteria Bacillus subtilis,
Enterococcus faecium, Enterococcus faecalis, Strepto-
coccus pneumoniae, Staphylococcus epidermidis, Sta-
phylococcus saprophyticus, and Micrococcus luteus.
This broad spectrum activity against important gram-
positive human pathogens but not against gram-nega-
tive bacteria with wild-type outer membranes indicates
that, like many other peptide and polyketide macro-
cyclic antibiotics including type B streptogramins, this
barrier is impermeable to these chimeric antibiotics.
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232Table 2. Inhibition of Bacterial Growth by Chimeric Antibiotics
Zone of Inhibition (cm)
Bacterial Strain Quinupristin Compound 5 Compound 6e Compound 7e Compound 8
Escherichia coli BAS901 2.2 1.1
E. coli BAS901/pUC19 2.2 1.1 1.2 1.2 n.i.
E. coli BAS901/pUCVgb n.i.a 1.1 1.3 1.3 n.i.
Bacillus subtilis 1A752 1.8 1.1
B. subtilis W23 2.1 0.9
B. subtilis L5706 2.1 0.8
B. subtilis 168 2.2 0.8
Micrococcus luteus 2.7 1.0
Enterococcus faecium CP54-32 1.8 0.8
Enterococcus faecalis (ATCC 29212) 1.8 0.75
Enterococcus faecalis (ATCC 51299)b n.i. n.i.
S. saprophyticus (ATCC 15305) 2.3 0.8
Staphylococcus epidermidis (ATCC 12228) 3.4 0.85
Staphylococcus epidermidis (ATCC 14990) 3.0 0.75
Staphylococcus aureus (ATCC 43300)c n.i. n.i.
Staphylococcus aureus (ATCC 29213) 2.3 n.i. n.i.
Staphylococcus aureus (ATCC 25923) 2.2 n.i.
Staphylococcus aureus (ATCC 49476) 2.6 n.i.
Streptococcus pneumoniae (ATCC 6305) 2.1 0.8
Streptococcus pneumoniae (ATCC 49619) 2.0 n.i.
E. coli (ATCC 25922) n.i. n.i.
Salmonella enterica (ATCC 14028)d n.i. n.i.
Haemophilus influenza n.i. n.i.
a n.i., no inhibition of growth.
bVancomycin, aminoglycoside resistant Enterococcus faecalis.
cMethicillin resistant, oxacillin resistant Staphylococcus aureus.
d serovar Typhimurium.
e6 and 7 were analyzed following cyclization without further purification.coccus aureus is unknown at this time, however 5 does
inhibit the growth of this organism at 256 g/ml (Table
T3). The possibility that the elevated MIC could be the
B
result of the ribitol-based wall teichoic acid polymer in
Staphylococcus aureus was discounted as B. subtilis
OW23, which primarily synthesizes this polymer, was in-
hibited by 5 (Table 2). E
EComparison of the MIC values for quinupristin and 5
against control E. coli (BAS901/pUC19), E. coli express-
Eing the streptogramin inactivating enzyme Vgb (BAS901/
S
pUC19VGB), and E. coli with the ribosome protecting
enzyme Erm methyltransferase (BAS901/pUC19ermB) S
indicated that unlike quinupristin, the antibacterial ef-
fects of 5 are invariant in the presence of these resis-
Stance enzymes (Table 3). These results supported our
in vitro experiments demonstrating that 5 was not a
Ssubstrate for Vgb. Furthermore, 5 is not susceptible to
the target modification resistance afforded through ErmB- S
mediated methylation of the 23S rRNA of ribosome.
Quinupristin and dalfopristin act in a synergistic man-
Sner; we therefore explored whether 5 also could syner-
gize with dalfopristin. These experiments were per-
formed against both B. subtilis 1A752 and E. coli
S
BAS901 in microtiter plates using a standard checker-
board technique. The results revealed an additive, not
synergistic, effect with dalfopristin (see Supplemental E
Data). Although we did not observe a synergistic anti-
Smicrobial effect, we could not rule out the possibility
that 5 still bound the ribosome. It remained plausible
Sthat the structure of 5 precluded it from binding to the
same site as quinupristin on the ribosome and thus
synergy was not observed. This would also be consis-
a
tent with the in vivo results observed with ErmB.able 3. MIC Values for Quinupristin and 5 against Susceptible
acteria
MIC (g/ml)
rganism Quinupristin Compound 5
. coli BAS901/pUC19 4 32
. coli BAS901/ 16 32
pUC19ermB
. coli BAS901/pUCVgb >256 32
taphylococcus aureus 2 256
RN4220/pJIM2246
taphylococcus aureus 8a 256
RN4220/pJIM2246
ermB
taphylococcus aureus 8 256
RN4220/pJIM2246 vgb
taphylococcus aureus 4 256
(ATCC 29213)
taphylococcus 0.5 64
epidermidis (ATCC
12228)
taphylococcus 1 64
epidermidis (ATCC
14990)
taphylococcus 8 64
saprophyticus (ATCC
15305)
nterococcus faecalis 8 128
(ATCC 29212)
treptococcus 1 32
pneumoniae (ATCC 6305)
treptococcus 0.5 128
pneumoniae (ATCC
49619)
Indicates induction with quinupristin (1 g/ml).
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result of inhibition of translation, we measured the im-
pact of this compound on the efficiency of an in vitro
translation system. While the known inhibitors of trans-
lation chloramphenicol, erythromycin, and the strepto-
gramins dalfopristin and quinupristin did block in vitro
translation, compound 5 did not at 250 g/ml (Figure
4). Furthermore, fluorescence titration experiments with
purified intact E. coli ribosomes that measures increase
of the fluorescence associated with the Hpa moiety did
support ribosome binding by quinupristin as previously
shown [28], but compound 5 did not appear to interact
with the ribosome in this study (see Supplemental
Data).
Given that 5 is a chimera of tyrocidine, an antibiotic
that acts by disrupting cellular membranes, we exam-
ined the hemolytic activity of 5 in comparison with
the commercially available, channel-forming antibiotic
gramicidin S (tyrocidine is not commercially available).
Compound 5 showed no significant hemolytic proper-
ties even after a 9 hr exposure, while gramicidin lysed
cells rapidly under identical conditions (Supplemental
Data). Consistent with the lack of membrane damaging
activity was our observation that 5 is bacteriostatic and
not bactericidal against E. coli BAS901 and B. subtilis
1A752.
These results therefore indicate that the mode of ac-
tion of these chimeric antibiotics, rather unexpectedly,
do not parallel either type B streptogramins or channel
forming peptides. In an effort to further explore the im-
pact of altering the ester bond of type B streptogram-
ins, we prepared an analog of the antibiotic patricin A
replacing the Thr-phenylglycine cyclizing ester with the
diaminopropionic acid-phenylglycine amide (compound
8). This compound differs also from patricin A in the
lack of N methylation between amino acid residues 4
and 5. Compound 8 showed no antibacterial activityFigure 4. Impact of Antibiotics on In Vitro Translation
Antibiotics were added to a final concentration of 0.1 mg/ml and
the amount of [35S]-Met incorporated into in vitro translated chlor-
amphenicol acetyltransferase quantified and normalized to the
DMSO carrier control. The average of two experiments is pre-
sented. Duplicate values were within 6% of each other.nor did it inhibit in vitro translation (Table 2 and Figure
4). These results demonstrate strict structural require-
ments for streptogramin antibiotic activity. The chimeric
antibiotics described in this work therefore serendipi-
tously represent, to our knowledge, a new class of anti-
microbial peptides of unknown function.
While a rigorous structure activity relationship was
beyond the purpose of this study, we can make some
general comments regarding the properties of these
antibiotics. First, there is good tolerance of amino acid
side chains in position 3. Second, the 3-Hpa is impor-
tant in position 1. Cyclic depsipeptides 1 and 2, where
the hydroxyl of 3-Hpa is protected with a benzyl group
and 3 and 4, with a picolinic acid devoid of the hydroxyl
at position 3, showed no antimicrobial activity. Admit-
tedly these are depsipeptide and not peptides such as
5, 6, and 7, therefore we cannot rule out that the cycliz-
ing functionality may impact on activity as well. Further
exploration of the additional details of structure versus
activity will expand on our understanding of the bio-
chemistry of these antibiotics.
Significance
The rampant increase in the number of antibiotic-
resistant organisms has placed great pressure on the
pharmaceutical, medical, and academic fields to gain
a better understanding of the mechanism of resis-
tance, and for developing new antimicrobials that can
be used to combat these organisms. Our previous re-
search had demonstrated that type B streptogramins
are inactivated by Vgb lyase through elimination of
the ester bond which joins the N and C termini of the
peptide [14]. In this work, we have shown that strepto-
gramin-tyrocidine chimeras possess encouraging
antibacterial properties, and are simultaneously unaf-
fected by the resistance afforded by Vgb lyase and
by ErmB through methylation of the ribosome. This
finding opens the possibility for further development
of a class of chimeric antibiotics that evade resis-
tance mechanisms preexisting in the clinic.
Experimental Procedures
Reagents and General Techniques
PEGA-NH2 and sulfamylbutyryl resins, and all Fmoc and Boc-pro-
tected amino acids, except Fmoc-dAbu-OH, were purchased from
Novabiochem. Recombinant Vgb from Staphylococcus aureus and
truncated tyrocidine thioesterase (TycC TE) were expressed and
purified as previously described [14, 20]. LC/MS was conducted on
a Micromass Quatro LC by Dr. K. Green at the McMaster Regional
Centre for Mass Spectrometry.
Solid-Phase Synthesis of Peptides
We used two solid-phase strategies to achieve the synthesis of
cyclic peptides. The first was a recently described biomimetic ap-
proach on PEGA-NH2 resin that uses a CoA-mimicking linker fol-
lowed by sequential attachment of the Fmoc-protected amino
acids and enzymatic cyclization [17]. In the second approach, stan-
dard Fmoc-amino acids were loaded on sulfamylbutyryl resin.
The general synthesis of the linear peptides followed the follow-
ing procedure: to the resin loaded with the first amino acid (1 g)
was added 10 ml of 20% piperidine in dimethylformamide (DMF)
solution, followed by agitation for 20 min and wash cycles of DMF
(3 × 10 ml), iso-propanol (3 × 10 ml), and DMF (2 × 10 ml). Subse-
quently, a freshly prepared mixture of the Fmoc-protected amino
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234acid (Fmoc-AA-OH) (5eq), 1-hydroxybenzotriazole (5 eq), PyBop (5 1
1eq), and diisopropylethylamine (DiPEA) (10 eq) in DMF (5 ml) was
added and the reaction mixture was agitated for 2 to 4 hr. The
washing cycle was repeated and the resulting resin was subjected
to Kaiser test [29] to assess the efficiency of coupling. If the test P
was positive, the coupling was repeated until a negative test result S
was obtained. Otherwise, the synthesis proceeded to the next A
round of deprotection and coupling. Following the coupling of the m
last amino acid to the resin, the protected peptide was treated with T
10 ml of trifluoroacetic acid (TFA)/water/triisopropylsilane (TIPS) d
(9.5:0.25:0.25) for 2 hr at room temperature and washed sequen- m
tially with DMF, iso-propanol, and methanol and dried over KOH e
under vacuum for 4 hr. s
p
tTycC TE Catalyzed Peptide Cyclization
Purified recombinant TycC TE was added to 200–500 mg of depro-
etected peptide on PEGA resin as described in [17] for 30 min. The
mixture was then filtered and the process repeated. The resin was
psubsequently washed twice with acetonitrile and the soluble frac-
ptions pooled, lyophilized, and analyzed by LC/MS.
5
G
Base-Promoted, On-Resin Peptide Cyclization s
On-resin cyclization of the linear peptide precursor was carried out s
by immersing the resin in 2% DiPEA in THF (200 ml) for 16 hr at E
room temperature [25]. After filtration the solvent was removed in t
vacuo, the crude product was resuspended in 50% acetonitrile/ u
water, and the solution lyophilized. The final product was charac- w
terized by LC-MS analysis and purified by preparative reverse q
phase HPLC (Vydac 218TP1022 column). a
a
pSynthesis of Peptides on Sulfamylbutyryl Resin
B
Peptide 5 was synthesized on sulfamylbutyryl resin (1 g) following
t
the general procedure described above. 3-Hydroxypicolinic acid
d
(3-Hpa) was the last amino acid to be incorporated in the peptide
s
chain after trityl group deprotection of diaminopropionic acid with
B
a mixture of 3% TFA, 5% TIPS, and 92% DCM (10 ml) for 2 hr at
room temperature. At the end of the peptide synthesis, the resin
Dwas activated with iodoacetonitrile as already described [30]. Boc-
Tdeprotection was carried out using a mixture of TFA/phenol/TIPS/
iwater (8.8:0.5:0.5:0.2) (10 ml) for 2 hr at room temperature. The
scyclization reaction was carried out as described above and the
apeptide product purified by reverse phase HPLC in an overall yield
tof 10 mg (1.3%).
s600 MHz, 1H-NMR spectra data for 5 in 60:40 CD3CN:D2O, δ ppm,
tJ in Hz: 0.78 (d, 3H, J 6.5); 0.83 (d, 3H, J 6.5); 1.12 (d, 3H, J 3.8);
t1.21–1.27 (m, 1H); 1.33–1.39 (m, 1H); 1.41–1.49 (m, 2H); 1.63–1.77
T(m, 8H); 1.81–1.83 (m, 1H); 2.78–2.82 (m, 4H); 2.84–2.98 (m, 1H),
t3.06–3.10 (m, 4H); 3.46–3.50 (m, 2H); 3.57–3.61 (m, 2H); 3.64–3.68
S(m, 2H); 4.15–4.17 (m, 1H); 4.21–4.23 (m, 1H); 4.25–4.30 (m, 1H);
a4.33–4.41 (m, 1H); 4.64–4.68 (m, 1H); 4.73–4.75 (t, 1H, J1 5.2, J2 5.2);
7.06–7.29 (m, 10H); 7.37–7.39 (d, 1H, J 8.5); 7.47–7.50 (m, 1H); 7.57–
H7.61 (m, 1H); 7.83–7.85 (t, 1H, J1 6.1, J2 5.9); and 7.89–7.93 (m, 2H).
H13C NMR: 18.62, 19.88, 22.64, 22.69, 24.07-24.13, 25.38, 29.04,
s29.89, 36.36, 37.32, 39.61, 41.04–41.17, 48.02, 59.91, 54.25–54.48,
t56.29, 59.83, 61.15, 67.32, 127.78, 128.10, 129.43–129.51, 130.13–
m130.26, 136.92, 138.21, 158.40, 162.41, 168.75, 172.31–172.47,
g173.30–173.41, 173.95, and 174.51.
bTOF MS ES+ m/z 927.4754 ([M+H]+, calculated m/z for
wC47H62N10O10, 926.4650).
The patricin analog 8 was synthesized using the same solid
phase strategy as for the synthesis of peptide 5. The cyclized pro- I
Iduct was purified using reverse phase HPLC.
700 MHz, 1H-NMR spectra data for 8 in 60:40 CD3CN:D2O, δ ppm, T
pJ in Hz:
0.86 (t, 3H, J1 3.8, J2 3.6); 1.66–1.72 (m, 2H); 1.85–1.95 (m, 4H); t
D2.05–2.15 (m, 4H); 2.80–2.91 (m, 2H); 3.06–3.21 (dd, 2H); 3.38–3.53
(m, 4H); 3.56–3.62 (m, 2H); 3.67–3.74 (m, 2H); 4.15–4.20 (m, 1H); a
o4.25–4.29 (m, 1H); 4.30–4.38 (m, 2H); 4.81–4.84 (m, 1H); 4.85 (d, 1H,
J 7.1); 5.13–5.20 (m, 1H); 7.09–7.11 (m, 4H); 7.13–7.55 (m, 6H); 7.61– c
o7.71 (m, 2H); 8.18–8.21; and 8.57–8.59 (m, 1H).
13C NMR: 10.24, 23.87, 24.22, 26.25, 29.24, 30.20, 37.64, 48.47, r
a51.16, 53.16, 53.24, 55.63, 60.26, 61.60, 61.89, 119.31, 127.34, 127.88,29.25, 129.53, 129.64, 129.95, 130.27, 130.48, 132.02, 137.10, 138.00,
41.64, 158.15, 170.33, 172.13, 172.26, 173.35, 173.87, and 174.59.
MS ES+ m/z 767.8 [M+H]+, calculated m/z for C40H46N8O8 766.8.
reparation of Streptogramin-Sensitive, E. coli-Expressing
treptogramin B Resistance Elements
hyperpermeable E. coli strain, E. coli BAS901, harboring a plas-
id constitutively expressing Vgb was created for in vivo studies.
he plasmids pVGB, described previously in [14], and pUC19 were
igested with XbaI and BamHI, to yield an approximately 1 kb frag-
ent containing a ribosomal binding site upstream of vgb, and lin-
arized pUC19 backbone, respectively. The vgb fragment was then
ubcloned into the linearized pUC19 backbone downstream of
Lac yielding pUC19-VGB. Both pUC19-VGB and pUC19 were
ransformed into E. coli BAS901.
In order to test the effects of 5 against E. coli BAS901 harboring
rmB, the 23S rRNA methyltransferase, the plasmid pJIM2246
ermB [13] was purified from Staphylococcus aureus RN4220/
JIM2246 ermB. ermB was subsequently amplified from
JIM2246 ermB via polymerase chain reaction using primers
#-GAATTCCATATGAACAAAAATATAAAATATTCTCAAAAC and 5#-
AATTCGGATCCTCATAGAATTAATTTCCTCCCG (engineered re-
triction enzyme sites are underlined). The amplified product was
ubcloned into pCR4Blunt-TOPO (Invitrogen) and transformed into
. coli XL10 GOLD, resulting in ermB being positioned in frame with
he lacZ gene. This construct, designated pTOPOerm, was then
sed as template in the reamplification of ermB using a new for-
ard primer containing a strong ribosomal binding consensus se-
uence (shown in italics); 5-ATCTAGAGGAGGAATTCCATATG. The
mplification product was again subcloned into pCR4Blunt-TOPO
nd transformed into XL10 GOLD, resulting in the construct
TOPOnewerm. pTOPOnewerm was digested with PstI and
amHI, and the resulting fragment contained ermB downstream of
he ribosomal binding site. This fragment was ligated to pUC19
igested with the same restriction enzymes. The resulting con-
truct, pUC19-ermB was subsequently transformed into E. coli
AS901.
etermination of Antibiotic Activity of Peptides
he antibiotic activity of the peptides synthesized in this study was
nitially assayed using a disk assay where samples were applied to
terile paper disks placed on a fresh lawn of bacterial culture on
ppropriate agar plates as required by the organism. These were
hen incubated for 16 hr at 37°C and the zone of growth inhibition
urrounding the disks recorded. For quantitative assessment of an-
ibiotic activity in liquid culture, the minimal inhibitory concentra-
ion (MIC) of peptides was determined by serial dilution studies.
he peptides and standard antibiotics were dissolved in DMSO and
he final concentration of DMSO in the liquid cultures was 5%. Both
. aureus RN4220 and E. coli BAS901 were able to grow efficiently
t this level of DMSO.
emolysis Assay
uman red blood cells were freshly harvested, washed with 0.85%
aline solution with 5 mM EDTA and resuspended in the same solu-
ion to an A412 of 0.6. The hemolysis assay was performed in 1.5
l Eppendorf tubes with the addition of either 5 in DMSO, saline,
ramicidin (final concentration 30 g/ml), or DMSO (5% final), for
oth 3 and 9 hr at 37°C with occasion gentle mixing. The mixtures
ere then centrifuged and the A412 of the supernatant measured.
n Vitro Translation Assay
nhibition of translation was monitored using an ActivePro In Vitro
ranslation Kit from Ambion. Briefly, a reaction mixture was pre-
ared as per the manufacturer’s instructions that contained all of
he constituents necessary (including [35S]-methionine) except for
NA template. These mixtures were then preincubated for 15 min
t room temperature in the presence or absence of various antibi-
tics. Subsequent to the preincubation period, a control template
ontaining a chloramphenicol acetyltransferase gene under control
f a bacteriophage T7 promoter was added and the reaction car-
ied out for 1 hr at 37°C. Due to the insoluble nature of some of the
ntibiotics, the final DMSO concentration in each reaction including
Chimeric Streptogramin-Tyrocidine Antibiotics
235controls was maintained at 5% (v/v). Aliquots were taken after 1
hr, and separated on SDS polyacrylamide gels. The efficiency of
translation of 35S-labeled chloramphenicol was analyzed and
quantified using a Typhoon 9200 variable mode imager (Image-
Quant 5.2 software).
Supplemental Data
Supplemental Data for this article is available online at http://
www.chembiol.com/cgi/content/full/12/2/229/DC1/.
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